CONFERENCE UPDATES: WCLC 2021
Combination of durvalumab, tremelimumab and chemotherapy as a potential new first-line mNSCLC treatment option
- Melissa L et al. Durvalumab ±Tremelimumab + Chemotherapy as First-Line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study. Presented at IASLC 2021 World Conference on Lung Cancer; September 8-14, 2021.
Fixed-duration immunotherapy demonstrates comparable survival benefits in advanced NSCLC
Immune checkpoint inhibitor (ICI)-based treatments are one of the front-line options for patients with advanced non-small cell lung cancer (NSCLC).1 However, no optimal duration has been defined.1 At the ASCO 2023 Annual Meeting, Dr. Lova Sun from the University of Pennsylvania, the United States (US), presented the results of a US study that investigated the clinical practice patterns surrounding ICI treatment discontinuation at 2 years.1 Furthermore, the association between the duration of therapy with overall survival (OS) was evaluated by comparing patients who received ICIs for 2 years with those who had received ICIs beyond 2 years.1
Adjuvant osimertinib and multidisciplinary-team approach in early-stage NSCLC management: A local case sharing
Non-small cell lung cancer (NSCLC) accounts for 85%of all types of lung cancer and is the most common cancer in Hong Kong with a total of 5,575 cases in 2019.1,2 Approximately 30% of NSCLC patients are diagnosed as early stage, and surgical resection is the preferred treatment option for possibly co
Adopting durvalumab consolidation therapy: A breakthrough for non-small cell lung cancer treatment
Despite recent advances in oncology, drug resistance and disease relapse have remained a significant unmet need among non-small cell lung cancer (NSCLC). Recently, the development of novel therapeutics including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have made multiple breakthroughs in the treatment of NSCLC. In a virtual meeting and clinical debate, “Durvalumab in EGFRm Stage III NSCLC – To Offer or Not to Offer?”, Dr. Victor Lee summarized the key studies of NSCLC treatments, including the phase 3 PACIFIC trial of an anti-programmed cell death receptor ligand 1 (PD-L1) drug, durvalumab. Dr. Oscar Chan and Dr. Jonathan Nyaw then discussed the applications and other considerations of the durvalumab regimen among stage 3 Epidermal Growth Factor Receptor mutated (EGFRm) NSCLC patients in the clinical setting.
A milestone in biomarker testing and therapies for lung cancer
With advancement in biomarker-driven treatment and targeted therapies for lung cancer, novel strategies are employed to optimize personalized regimens for different subtypes of lung cancer.1 To keep track of the evolving lung cancer management, a symposium regarding biomarker and treatment landscape for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) was held at the World Conference on Lung Cancer 2021.1